Denali Therapeutics Toekomstige groei
Future criteriumcontroles 2/6
Denali Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 26.8% en 53% per jaar. De winst per aandeel zal naar verwachting groeien met 29.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -59.1% zijn.
Belangrijke informatie
26.8%
Groei van de winst
29.56%
Groei van de winst per aandeel
| Biotechs winstgroei | 27.7% |
| Inkomstengroei | 53.0% |
| Toekomstig rendement op eigen vermogen | -59.11% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 11 Aug 2026 |
Recente toekomstige groei-updates
Recent updates
Nieuw narratief • Aug 21
Blood Brain Barrier Platform And Rare Disease Pipeline Will Shape Long Term Neurology Potential
Catalysts About Denali Therapeutics Denali Therapeutics develops biologic medicines designed to cross the blood brain barrier for rare genetic and common neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Aug 13
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One
Summary Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech with AVLAYAH, its FDA-approved rare-disease therapy. AVLAYAH's Q2 revenue of $3.6M is projected to triple in Q3, reflecting accelerating patient uptake and payer coverage progress. DNLI's TransportVehicle platform underpins a pipeline spanning enzymes, antibodies, and oligonucleotides, targeting both rare and large neurodegenerative markets. Valuation requires execution: AVLAYAH's commercial ramp and zafinofusp alfa's progress are critical, while Alzheimer’s programs offer significant long-term optionality. Read the full article on Seeking Alpha
Nieuw narratief • Aug 07
Brain Delivery Platform And Rare Disease Portfolio Will Support Long-Term Upside Potential
Catalysts About Denali Therapeutics Denali Therapeutics focuses on biologic medicines engineered to cross the blood brain barrier for rare genetic and common neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?Analyse-artikel • May 08
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Mar 20
Denali Therapeutics: Vast Pipeline, First Approval Up Ahead
Summary Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 shows strong biomarker data for Hunter syndrome, with plans for a BLA submission and accelerated approval by Q2 2025. The Biogen partnership for Parkinson’s Disease asset DNL151 includes substantial milestone payments and profit-sharing, highlighting its potential impact. Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock prices. Read the full article on Seeking AlphaSeeking Alpha • Jan 09
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Summary Denali Therapeutics Inc.'s DNL343 failed to meet the primary endpoint in the phase 2/3 HEALY ALS trial, but potential biomarker analyses in 2025 may offer a path forward. Despite the trial setback in ALS, Denali's stock remains stable due to continued pre-specified analyses expected in late 2025. BLA filing of tividenofusp alfa for the treatment of patients with MPS II remains on track under the Accelerated Approval Pathway Program in early 2025. Financially, Denali has $1.28 billion in cash but may need additional funding in 2025, posing a risk of shareholder dilution. Read the full article on Seeking AlphaAnalyse-artikel • Dec 09
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Aug 20
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
Summary Denali Therapeutics' proprietary Transport Vehicle technology enables drug delivery across the blood-brain barrier, targeting neurodegenerative diseases. DNL310, targeting MPS II, and DNL343 for ALS are key drug candidates with potential, though competition is significant. The company’s $500 million capital raise supports its aggressive R&D investment, providing a runway for developing its pipeline. Despite its promising platform, DNLI still has a relatively high cash burn and regulatory hurdles before achieving drug approval. Due to Denali's high-risk, long-term biotech development, I deem DNLI a DCA "buy" for investors who understand the inherent risks. Read the full article on Seeking AlphaAnalyse-artikel • Jul 26
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analyse-artikel • May 23
Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%
Denali Therapeutics Inc. ( NASDAQ:DNLI ) shareholders would be excited to see that the share price has had a great...Seeking Alpha • May 13
Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
Summary Denali Therapeutics Inc.'s DNL-310 is currently being explored in an ongoing phase 2/3 COMPASS study for treatment of patients with MPS II; Enrollment completion expected in 2024. Denali is in talks with CDER division of FDA to seek for Accelerated Approval pathway for DNL-310 for the treatment of patients with MPS II. Biomarker and safety data from a phase 1/2 study, using DNL-126 for the treatment of patients with MPS IIIA, expected end of 2024. Another promising program from the pipeline is the development of DNL-343, which is being advanced in the phase 2/3 HEALEY ALS Platform trial for treatment of patients with amyotrophic lateral sclerosis. Read the full article on Seeking AlphaAnalyse-artikel • Apr 17
An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Denali Therapeutics fair value estimate is US$30.71 Denali...Analyse-artikel • Mar 21
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Those holding Denali Therapeutics Inc. ( NASDAQ:DNLI ) shares would be relieved that the share price has rebounded 25...Seeking Alpha • Mar 07
Denali: Leveraging Transport Vehicle Technology For Neurological Gains
Summary Denali's stock performance has been flat despite the biotech sector's 20% rise; recently raised $500 million in a PIPE. ALS trial failure with partner Sanofi pressured stock; Denali's focus is on transport vehicle (TV) technology and BBB crossing. Denali boasts a strong financial position with $1.53 billion in cash, extending operational runway significantly. Recommends "buy" based on Denali's innovative TV technology, financial health, and potential in neurological disorders despite biotech risks. Read the full article on Seeking AlphaAnalyse-artikel • Feb 21
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Analyse-artikel • Jan 26
Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet
Denali Therapeutics Inc.'s ( NASDAQ:DNLI ) price-to-sales (or "P/S") ratio of 7x might make it look like a buy right...Analyse-artikel • Nov 20
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analyse-artikel • Oct 09
Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking
With a median price-to-sales (or "P/S") ratio of close to 10.4x in the Biotechs industry in the United States, you...Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 310 | -375 | -22 | -173 | 15 |
| 12/31/2027 | 129 | -453 | 8 | -349 | 19 |
| 12/31/2026 | 61 | -452 | -433 | -330 | 19 |
| 6/30/2026 | 4 | -511 | -466 | -434 | N/A |
| 3/31/2026 | N/A | -508 | -419 | -412 | N/A |
| 12/31/2025 | N/A | -513 | -422 | -413 | N/A |
| 9/30/2025 | N/A | -499 | -411 | -398 | N/A |
| 6/30/2025 | N/A | -479 | -368 | -350 | N/A |
| 3/31/2025 | N/A | -454 | -384 | -366 | N/A |
| 12/31/2024 | N/A | -423 | -364 | -348 | N/A |
| 9/30/2024 | N/A | -427 | -376 | -363 | N/A |
| 6/30/2024 | 1 | -420 | -402 | -391 | N/A |
| 3/31/2024 | 295 | -137 | -425 | -413 | N/A |
| 12/31/2023 | 331 | -145 | -371 | -358 | N/A |
| 9/30/2023 | 341 | -124 | -348 | -332 | N/A |
| 6/30/2023 | 343 | -128 | -321 | -302 | N/A |
| 3/31/2023 | 101 | -371 | -248 | -231 | N/A |
| 12/31/2022 | 108 | -326 | -263 | -245 | N/A |
| 9/30/2022 | 111 | -303 | -254 | -238 | N/A |
| 6/30/2022 | 112 | -284 | -234 | -222 | N/A |
| 3/31/2022 | 83 | -286 | -243 | -233 | N/A |
| 12/31/2021 | 49 | -291 | -220 | -211 | N/A |
| 9/30/2021 | 353 | 30 | 361 | 368 | N/A |
| 6/30/2021 | 357 | 56 | 404 | 410 | N/A |
| 3/31/2021 | 340 | 58 | 415 | 420 | N/A |
| 12/31/2020 | 336 | 71 | 413 | 416 | N/A |
| 9/30/2020 | 24 | -228 | -150 | -145 | N/A |
| 6/30/2020 | 28 | -216 | -183 | -176 | N/A |
| 3/31/2020 | 26 | -215 | N/A | -176 | N/A |
| 12/31/2019 | 27 | -198 | N/A | -152 | N/A |
| 9/30/2019 | 148 | -66 | N/A | -11 | N/A |
| 6/30/2019 | 135 | -55 | N/A | -15 | N/A |
| 3/31/2019 | 133 | -52 | N/A | -14 | N/A |
| 12/31/2018 | 129 | -36 | N/A | 50 | N/A |
| 9/30/2018 | 3 | -137 | N/A | -61 | N/A |
| 6/30/2018 | 2 | -123 | N/A | -49 | N/A |
| 3/31/2018 | 1 | -91 | N/A | -24 | N/A |
| 12/31/2017 | N/A | -88 | N/A | -77 | N/A |
| 9/30/2017 | N/A | -85 | N/A | -77 | N/A |
| 6/30/2017 | N/A | -93 | N/A | -76 | N/A |
| 3/31/2017 | N/A | -90 | N/A | -75 | N/A |
| 12/31/2016 | N/A | -87 | N/A | -72 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat DNLI de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat DNLI de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat DNLI de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van DNLI ( 53% per jaar) zal naar verwachting sneller groeien dan de markt US ( 12.9% per jaar).
Hoge groei-inkomsten: De omzet van DNLI ( 53% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat DNLI binnen 3 jaar verliesgevend zal zijn.
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/21 10:09 |
| Aandelenkoers aan het einde van de dag | 2026/08/21 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Denali Therapeutics Inc. wordt gevolgd door 33 analisten. 19 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | Baird |
| Joel Beatty | Baird |
| Charles Moore | Baird |